home / stock / vtgn / vtgn news

VTGN News and Press, VistaGen Therapeutics Inc. From 08/11/23

Stock Information
Company Name: VistaGen Therapeutics Inc.
Stock Symbol: VTGN
Market: NASDAQ
Website: vistagen.com
Menu
VTGN VTGN Quote VTGN Short VTGN News VTGN Articles VTGN Message Board
Get VTGN Alerts

News, Short Squeeze, Breakout and More Instantly...
VTGN - TGTX, NKTR and AMLI among pre-market losers

2023-08-11 08:16:36 ET Cano Health ( CANO ) -48% after Q2 earning release . Yield10 Bioscience ( YTEN ) -46% . Maxeon Solar Technologies, Ltd. ( MAXN ) -26% after Q2 earning release . LQR House ( LQR ) -17% . Vistagen Therapeutics ( ...
VTGN - VistaGen Therapeutics GAAP EPS of -$0.94 misses by $0.08, revenue of $0.17M

2023-08-10 17:22:39 ET VistaGen Therapeutics press release ( NASDAQ: VTGN ): Q1 GAAP EPS of -$0.94 misses by $0.08 . Revenue of $0.17M (-45.2% Y/Y). For further details see: VistaGen Therapeutics GAAP EPS of -$0.94 misses by $0.08, revenue of $0.17M

VTGN - Subsequent to the Release of Positive Phase 3 Trial Results, Vistagen Provides Corporate Update and Reports Fiscal 2024 First Quarter Financial Results

Positive top-line results from Phase 3 PALISADE-2 trial of rapid-onset fasedienol (PH94B) nasal spray in social anxiety disorder (SAD) Itruvone (PH10) nasal spray now staged for Phase 2B clinical development as a stand-alone, non-systemic treatment for major depressive disorder (MDD) ...

VTGN - VTGN, YTEN and MF are among pre market gainers

2023-08-10 08:27:32 ET Capri Holdings ( CPRI ) +57% confirms $8.5B deal to acquire Capri Holdings. Edible Garden AG ( EDBL ) +43% Q2 earnings call release Missfresh Limited ( MF ) +27% . AppLovin Corporation ( APP ) +26% surges as BofA says 'multi...
VTGN - InvestorNewsBreaks - Vistagen Therapeutics Inc. (NASDAQ: VTGN) Schedules Release of Q1 2024 Numbers, Corporate Update Conference Call

Vistagen Therapeutics (NASDAQ: VTGN) , a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, has announced plans to report its Q1 2024 financial ...

VTGN - Vistagen To Report First Quarter Financial Results and Host Corporate Update Conference Call on August 10, 2023

Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced it will host a conference call and webcast on Thursday, August 1...

VTGN - CRDF, INFI and GRRR among mid-day movers

2023-08-08 12:46:20 ET Gainers: Infinity Pharmaceuticals ( INFI ) +56% . Bright Minds Biosciences ( DRUG ) +46% . Tilray Brands ( TLRY ) +31% . Paymentus Holdings (PAY) +33% . Gorilla Technology Group ( GRRR ) +28% . Cardiff Onco...
VTGN - Bright Minds, Bionomics top healthcare gainers; Vistagen, AxoGen among losers

2023-08-08 10:21:19 ET Gainers: Bright Minds Biosciences ( DRUG ) +62% . Bionomics ( BNOX ) +24% . Novo Nordisk ( NVO ) +18% . Quanterix ( QTRX ) +17% . Tilray Brands ( TLRY ) +18% . Losers: Vistagen Therapeutics ( VTGN ...

VTGN - NKLA, MDB and PTRA among pre-market losers

2023-08-08 08:25:37 ET Proterra ( PTRA ) -67% announces strategic initiatives to trengthen financial position and sharpen technology focus. Datasea ( DTSS ) -35% . Save Foods ( SVFD ) -29% . Missfresh Limited ( MF ) -26% . Alteryx ( AYX ...

VTGN - VistaGen Therapeutics Inc. (NASDAQ: VTGN) Near the Top of Equities by Percentage Gain on 8/7

VistaGen Therapeutics, Inc. (NASDAQ: VTGN) is one of today's top gainers. The company's shares are currently up 877.38% on the day to $16.42. VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential ...
Previous 10 Next 10